Technical Analysis for ALT - Altimmune, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 9.08 | -7.91% | -0.78 |
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Centerline Cross | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Resistance | Bearish | -7.91% | |
Stochastic Reached Oversold | Weakness | -7.91% | |
Multiple of Ten Bearish | Other | -7.91% | |
Wide Bands | Range Expansion | -7.91% | |
Oversold Stochastic | Weakness | -7.91% | |
Fell Below 20 DMA | Bearish | -9.43% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 19 hours ago |
1.5x Volume Pace | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 3% | about 20 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/26/2024
Altimmune, Inc. Description
Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Phosphates Manufacturing Process Vaccines Reversal Manufacturing Processes Nerve Biodefense Choline Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.84 |
52 Week Low | 2.09 |
Average Volume | 6,095,709 |
200-Day Moving Average | 5.37 |
50-Day Moving Average | 10.32 |
20-Day Moving Average | 10.60 |
10-Day Moving Average | 10.37 |
Average True Range | 1.10 |
RSI (14) | 42.53 |
ADX | 15.36 |
+DI | 25.01 |
-DI | 29.39 |
Chandelier Exit (Long, 3 ATRs) | 11.54 |
Chandelier Exit (Short, 3 ATRs) | 11.33 |
Upper Bollinger Bands | 13.55 |
Lower Bollinger Band | 7.65 |
Percent B (%b) | 0.24 |
BandWidth | 55.60 |
MACD Line | -0.02 |
MACD Signal Line | 0.21 |
MACD Histogram | -0.2346 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.18 | ||||
Resistance 3 (R3) | 10.28 | 10.03 | 9.99 | ||
Resistance 2 (R2) | 10.03 | 9.75 | 9.97 | 9.93 | |
Resistance 1 (R1) | 9.55 | 9.58 | 9.43 | 9.45 | 9.87 |
Pivot Point | 9.30 | 9.30 | 9.23 | 9.24 | 9.30 |
Support 1 (S1) | 8.82 | 9.02 | 8.70 | 8.72 | 8.29 |
Support 2 (S2) | 8.57 | 8.85 | 8.51 | 8.23 | |
Support 3 (S3) | 8.09 | 8.57 | 8.17 | ||
Support 4 (S4) | 7.99 |